Table 2.
Baseline characteristics
| Characteristic | Total (N = 63) |
10% (n = 17) |
5% (n = 16) |
0% (n = 14) |
10% + reset (n = 16) |
|---|---|---|---|---|---|
| Female, no. (%) | 33 (52) | 11 (65) | 7 (44) | 5 (36) | 10 (63) |
| Age group, years, no. (%) | |||||
| 4.0–7.4 | 30 (48) | 9 (53) | 8 (50) | 7 (50) | 6 (38) |
| 7.5–10.9 | 33 (52) | 8 (47) | 8 (50) | 7 (50) | 10 (62) |
| Mean ± SD | 7.6 ± 1.6 | 7.4 ± 1.4 | 7.5 ± 1.4 | 7.6 ± 1.9 | 8.1 ± 1.9 |
| Prior treatment | |||||
| Patching/atropine, no. (%) | 57 (90) | 16 (94) | 15 (94) | 14 (100) | 12 (75) |
| Binocular treatmenta | 5 (8) | 2 (12) | 2 (13) | 1 (7) | 0 (0) |
| Weeks in glasses at enrollment, no. (%) | |||||
| 8–13 | 2 (3) | 0 (0) | 0 (0) | 0 (0) | 2 (12) |
| 14–26 | 1 (2) | 0 (0) | 0 (0) | 1 (7) | 0 (0) |
| >26 | 60 (95) | 17 (100) | 16 (100) | 13 (93) | 14 (88) |
| Amblyogenic factor, no. (%) | |||||
| Strabismus | 16 (25) | 4 (24) | 6 (38) | 3 (21) | 3 (19) |
| Anisometropia | 28 (44) | 8 (47) | 4 (25) | 7 (50) | 9 (56) |
| Combined | 19 (30) | 5 (29) | 6 (38) | 4 (29) | 4 (25) |
| Amblyopic eye BCVA, logMAR, no. (%) | |||||
| 0.3–0.6 | 57 (90) | 14 (82) | 14 (88) | 14 (100) | 15 (94) |
| 0.7–0.8 | 6 (10) | 3 (18) | 2 (12) | 0 (0) | 1 (6) |
| Mean ± SD | 0.47 ± 0.14 | 0.50 ± 0.16 | 0.47 ± 0.16 | 0.46 ± 0.12 | 0.46 ± 0.14 |
| Fellow eye BCVA, logMAR, no. (%) | |||||
| −0.1 | 19 (30) | 6 (35) | 4 (25) | 4 (29) | 5 (31) |
| 0.0 | 29 (46) | 6 (35) | 8 (50) | 8 (57) | 7 (44) |
| 0.1 | 13 (21) | 5 (29) | 3 (19) | 1 (7) | 4 (25) |
| 0.2 | 2 (3) | 0 (0) | 1 (6) | 1 (7) | 0 (0) |
| Mean ± SD | 0.00 ± 0.09 | 0.01 ± 0.09 | −0.01 ± 0.09 | −0.01 ± 0.08 | −0.01 ± 0.08 |